Royalty Pharma stock is trading -41.82% below its average target price of $44.83 after dropping -4.3% during today's afternoon session. Analysts are giving the Large-Cap Pharmaceutical company an average rating of buy and target prices ranging from $28.0 to $60.0 per share.
The stock has an average amount of shares sold short at 3.8%, and a short ratio of 6.32. The company's insiders own 22.65% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that an average number of institutional investors are invested in the stock, with 72.2% of Royalty Pharma's shares being owned by this investor type.
Institutions Invested in Royalty Pharma
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-03-31 | Morgan Stanley | 10% | 44,217,885 | $1,153,202,437 |
| 2024-03-31 | Vanguard Group Inc | 8% | 37,699,682 | $983,207,703 |
| 2024-03-31 | FMR, LLC | 7% | 33,634,216 | $877,180,350 |
| 2024-03-31 | Blackrock Inc. | 5% | 21,205,841 | $553,048,331 |
| 2024-06-30 | Baillie Gifford and Company | 4% | 16,352,759 | $426,479,953 |
| 2024-03-31 | Viking Global Investors, L.P. | 3% | 11,485,547 | $299,543,064 |
| 2024-03-31 | Adage Capital Partners GP L.L.C. | 2% | 10,816,931 | $282,105,559 |
| 2024-06-30 | Swedbank | 2% | 10,813,470 | $282,015,296 |
| 2024-03-31 | State Street Corporation | 2% | 9,100,148 | $237,331,859 |
| 2024-03-31 | JP Morgan Chase & Company | 2% | 7,995,099 | $208,512,181 |
Besides an analyst consensus of strong upside potential, other market factors point to there being positive market sentiment on Royalty Pharma.
